Biosimilar, biobetter and next generation therapeutic antibodies.
作者信息
Beck Alain
出版信息
MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1.
Abstract
摘要
相似文献
1
Biosimilar, biobetter and next generation therapeutic antibodies.
MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1.
2
Implementation of the biosimilar pathway: economic and policy issues.
Seton Hall Law Rev. 2011;41(2):511-57.
3
Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
Ann N Y Acad Sci. 2017 Nov;1407(1):26-38. doi: 10.1111/nyas.13505. Epub 2017 Nov 1.
4
How similar do 'biosimilars' need to be?
Nat Biotechnol. 2004 Nov;22(11):1357-9. doi: 10.1038/nbt1104-1357.
5
Regulatory considerations for generic or biosimilar low molecular weight heparins.
Curr Drug Discov Technol. 2012 Jun 1;9(2):137-42. doi: 10.2174/1570163811209020137.
6
Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Seton Hall Law Rev. 2011;41(2):559-92.
7
SuperGenerics: a better alternative for biogenerics.
Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0.
8
Decision Science for Generic Drug Development and Review.
J Clin Pharmacol. 2019 Sep;59(9):1249-1251. doi: 10.1002/jcph.929. Epub 2019 May 14.
9
Progress and Hurdles for Follow-on Biologics.
N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6.
10
The similarity question for biologicals and non-biological complex drugs.
Eur J Pharm Sci. 2015 Aug 30;76:10-7. doi: 10.1016/j.ejps.2015.04.010. Epub 2015 Apr 23.
引用本文的文献
1
Characterization of pritumumab in murine models and primate safety study.
Sci Rep. 2025 Mar 25;15(1):10178. doi: 10.1038/s41598-025-95360-9.
2
A novel protein for bioremediation of gadolinium waste.
Protein Sci. 2025 Apr;34(4):e70101. doi: 10.1002/pro.70101.
3
Monoclonal antibodies: From magic bullet to precision weapon.
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
4
Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.
Immunohorizons. 2023 Dec 1;7(12):886-897. doi: 10.4049/immunohorizons.2300102.
5
Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems.
Front Pharmacol. 2023 Jun 22;14:1208277. doi: 10.3389/fphar.2023.1208277. eCollection 2023.
6
Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.
ACS Pharmacol Transl Sci. 2021 Mar 12;4(2):790-801. doi: 10.1021/acsptsci.0c00225. eCollection 2021 Apr 9.
7
Similar biologics in India: A story of access or potential for compromise?
Indian J Med Res. 2020 Nov;152(5):456-467. doi: 10.4103/ijmr.IJMR_43_18.
8
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
MAbs. 2021 Jan-Dec;13(1):1868078. doi: 10.1080/19420862.2020.1868078.
9
Glycoproteomics Technologies in Glycobiotechnology.
Adv Biochem Eng Biotechnol. 2021;175:413-434. doi: 10.1007/10_2020_144.
10
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.
Br J Clin Pharmacol. 2020 Nov;86(11):2114-2122. doi: 10.1111/bcp.14327. Epub 2020 May 13.
本文引用的文献
1
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.
Expert Opin Drug Discov. 2010 Jan;5(1):95-111. doi: 10.1517/17460440903413504. Epub 2009 Dec 1.
2
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
MAbs. 2011 Mar-Apr;3(2):111-32. doi: 10.4161/mabs.3.2.14788. Epub 2011 Mar 1.
3
The future of anti-CD20 monoclonal antibodies: are we making progress?
Blood. 2011 Mar 17;117(11):2993-3001. doi: 10.1182/blood-2010-07-298356. Epub 2011 Jan 5.
4
Hearing shines spotlight on biosimilar controversies.
Nat Rev Drug Discov. 2010 Dec;9(12):905-6. doi: 10.1038/nrd3325.
5
Antibody-based therapeutics to watch in 2011.
MAbs. 2011 Jan-Feb;3(1):76-99. doi: 10.4161/mabs.3.1.13895. Epub 2011 Jan 1.
6
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.
MAbs. 2011 Jan-Feb;3(1):67-75. doi: 10.4161/mabs.3.1.14021. Epub 2011 Jan 1.
7
The next generation of antibody-drug conjugates comes of age.
Discov Med. 2010 Oct;10(53):329-39.
8
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.
MAbs. 2010 Nov-Dec;2(6):613-24. doi: 10.4161/mabs.2.6.13333. Epub 2010 Nov 1.
9
Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
MAbs. 2010 Jul-Aug;2(4):379-94. doi: 10.4161/mabs.11986. Epub 2010 Jul 1.
10
Strategies and challenges for the next generation of therapeutic antibodies.
Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747.
Zotero 插件